← All trials
NCT05878691
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 28, 2022
- Primary completion
- Jul 30, 2027
- Completion date
- Jul 30, 2027
- First posted
- May 26, 2023
- Last posted
- Dec 6, 2023
- Enrollment
- 320
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Glenmark PharmaceuticalsLead sponsor
- Glenmark PharmaceuticalsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.